Introduction
============

Hepatocellular carcinoma (HCC) and hepatic metastasis of rectal cancer (HMRC) are common malignant lesions of the liver, as well as major causes of mortality due to their high risk and rapid development ([@b1-etm-0-0-9115]). According to recent statistics, HCC is the fourth most common cause of cancer-associated mortality worldwide ([@b4-etm-0-0-9115]). The incidence of HMRC has been reported to be \~25% at the time of diagnosis of rectal cancer ([@b5-etm-0-0-9115]). As these diseases exhibit distinctive biological activities, clinicians must identify the properties and tumor types of these hepatic lesions and provide different clinical treatment regimens to improve the surgical methods and patient survival rates.

Clinically, aside from laboratory examination, imaging-based differential diagnosis of these two diseases relies on traditional computed tomography (CT), magnetic resonance imaging (MRI) and ultrasonography ([@b6-etm-0-0-9115]). MRI was initially popular for the diagnosis of liver tumors; however, dynamic contrast-enhanced MRI (DCE-MRI) with quantitative or semi-quantitative functions has been gradually applied in clinical practice, as it provides a more comprehensive assessment of microvascular parameters and information in tumors compared with conventional contrast-enhanced MRI ([@b7-etm-0-0-9115]). Quantitative and semi-quantitative pharmacokinetic parameters can be produced by simulating the metabolic process of the contrast agent in the lesion ([@b7-etm-0-0-9115]). The endothelial transfer constant (K^trans^) reflects the microvascular changes in the lesion area, and the K^trans^ value in the tumor area is markedly increased compared with that in normal tissue, which may be used to observe the vascular permeability changes of the liver and tumor tissues ([@b8-etm-0-0-9115]). The initial area under the gadolinium concentration curve during the first 60 sec (IAUC) is a semi-quantitative parameter that represents the contrast agent concentration in the lesion during the first 60 sec ([@b9-etm-0-0-9115]). Hepatic perfusion index (HPI) refers to the hepatic artery blood supply fraction related to the portal vein as a reference standard; lesions with different pathogeneses have different HPI values ([@b10-etm-0-0-9115]). Previous studies have demonstrated that quantified pharmacokinetic parameters, such as K^trans^, IAUC and HPI, derived from DCE-MRI exhibit high potential in assessing liver tumors ([@b7-etm-0-0-9115]).

Radiomics analysis is a high-throughput automated computing method used to transform the gray information of the region of interest (ROI) into high-dimensional image features in medical images ([@b11-etm-0-0-9115]). The image features may provide assistance and support for the diagnosis, treatment assessment and prognosis in clinical practice with precise quantitative analysis ([@b11-etm-0-0-9115]). Previous studies have reported the application of this analysis in the differential diagnosis and grade malignancy detection of non-small cell lung cancer, keratoma and prostate cancer ([@b11-etm-0-0-9115]). Compared with traditional technical methods, radiomics analysis provides more diagnostic and differential diagnosis information. For example, Huang *et al* ([@b12-etm-0-0-9115]) evaluated lymph node metastasis in patients with colorectal cancer by combining the lymph node status reported by CT and radiomics analysis, which may be conveniently used to facilitate preoperative individualized prediction. In another study, Huang *et al* ([@b13-etm-0-0-9115]) evaluated a subset of radiomic features extracted from CT images; in contrast with previous studies, CT-based radiomics analysis revealed its potential use as a predicted imaging biomarker in the diagnosis of non-small cell lung cancer. Radiomics analysis provides information that cannot be observed by the naked eye, and indicates the property of the lesions by evaluating the radiomic features extracted from them ([@b11-etm-0-0-9115]).

Differential diagnosis of HCC and HMRC would benefit patients and clinical practice. Therefore, the present study aimed to evaluate the ability of pharmacokinetic parameters, as well as radiomic features derived from DCE-MRI, to differentiate HCC from HMRC.

Materials and methods
=====================

### Patient data

The patients provided written informed consent before undergoing DCE-MRI. A total of 75 patients (64 male and 11 female) with a mean age of 54.8±11.6 years (range, 25-78 years) were consecutively recruited between December 2018 and July 2019. The recruited patients were divided into two groups according to histopathological results: i) HCC, n=41 (35 male and 6 female); and ii) HMRC, n=34 (25 male and 9 female). The patients were selected according to the following criteria ([@b14-etm-0-0-9115]): i) The HCC group lesions were obtained from patients who suffered from a single lesion; ii) the HRMC group included the largest lesion selected from patients with ≤3 lesions; iii) the diameter of the lesions was 1-5 cm in both groups; iv) no contrast-enhanced MR examination had been performed within 30 days; v) all patients could follow the MR technician\'s request to complete the full scan. All lesions were histopathologically confirmed by surgery or biopsy 1 week after the MR examination. Patients with severe motion artifacts in the MRI and those who had received any antineoplastic treatment prior to their MR examination were excluded from the study.

### MRI acquisition

Imaging of the whole liver was performed on a 3.0T HDX TwinSP MR system (GE Healthcare) using an 8-channel abdominal phased array body coil. Prior to the examination, breathing exercise training was provided to patients. Routine axial images, including T1-weighted images (TR/TE, 2.7/1.2 msec; FOV, 410x287 mm; slice thickness/space, 6/2 mm; slab, 24), T2-weighted images (TR/TE, 6670/87 msec; FOV, 410x287 mm; slice thickness/space, 6/2 mm; slab, 24) and diffusion-weighted images (TR/TE, 5700/67 msec; b value, 1,000 sec/mm^2^; b value, 0), were first obtained. Multiple flip-angle images were collected using a 3D LAVA sequence (TR/TE, 2.8/1.3 msec; matrix, 288x188; FOV, 400x320 mm; phase FOV, 0.85; slice thickness/space, 6/2 mm; acceleration, 2.50; slab, 64; time resolution, 6.0 sec) with in-flip angles of 3, 6, 9, 12 and 15̊ ([@b14-etm-0-0-9115]).

DCE-MRI was performed with 22 acquiring phases in a 12-flip angle ([@b14-etm-0-0-9115]). Two unenhanced phases were first collected as the baseline. A contrast agent (Omniscan; GE Healthcare) was injected into the elbow vein at 2.0 ml/sec (0.3 mmol/kg) using a high-pressure injector (Mississippi^™^ XD 2000 Injector; Ulrich GmbH & Co. KG) and was effective from the third phase. Following injection, 20 ml saline was delivered at a rate of 2.0 ml/sec to flush the injector and its accessory tube.

### Data acquisition

A specialized medical image post-processing software package (OmniKinetics V2.0.10, GE Healthcare) for DCE-MRI was used in the present study ([@b14-etm-0-0-9115],[@b15-etm-0-0-9115]). First, the multiple flip angle images (3, 6, 9, 12 and 15˚) were imported into the software for T1 mapping calculation, and all DCE-MR images aligned by 3D non-rigid registration function, which attached to the OmniKinetics software, were subsequently loaded. Secondly, a dual-input two-compartment tracer kinetic liver model termed Extended Tofts was selected from OmniKinetics. Hepatic artery and portal vein ROIs were drawn by hand, and were performed by two radiologists in consensus, both with 8 and 12 years of experience, respectively, to obtain the arterial input function (AIF) and portal input function (PIF) of the contrast agent time-concentration curve. The contrast agent time-concentration curve of the dual vascular input function (VIF) in the liver ([Fig. 1](#f1-etm-0-0-9115){ref-type="fig"}) was fitted by AIF and PIF. The ROI of the hepatic artery was placed on the abdominal aorta near the entrance of the celiac trunk, replacing the hepatic artery, and the ROI of the portal vein was placed on the main portal vein. Thirdly, two radiologists with 8 and 12 years of experience in MRI reviewed the DCE-MRI, and the images were selected from the phase that corresponded to the peak of hepatic artery enhancement based on AIF. A consensus was reached through consultation. An oval or polygonal ROI was manually drawn along the edge of the largest cross-section of the lesion, and image segmentation of the ROI lesion was obtained. Finally, pharmacokinetic parameters and radiomic features were calculated using the 'calculate' function of the OmniKinetic software. The values of the pharmacokinetic parameters were obtained, including K^trans^, IAUC and HPI, which contributed to the differentiation of liver tumors in previous studies ([@b7-etm-0-0-9115]) and were thus used in the present study. The values of radiomic features were calculated using the 'CalcTexturePragram' function of the software ([Fig. 2](#f2-etm-0-0-9115){ref-type="fig"}). Three successive ROIs based on the largest cross-section of the lesion, including the upper and lower layers, were measured for pharmacokinetic parameters and radiomic features, and the mean values of the three measurements were calculated by clicking the 'merge' button on the software.

The radiomic features derived from the lesion DCE-MRI were selected in the phase when AIF reached the peak of the contrast agent time-concentration curve of the hepatic artery ([@b14-etm-0-0-9115],[@b15-etm-0-0-9115]). These parameters, which were calculated by OmniKinetics software, included five types of features: First order, histogram, gray level co-occurrence matrix, Haralick and run length matrix. The features are listed in [Table I](#tI-etm-0-0-9115){ref-type="table"}.

### Statistical analysis

R package version 3.5.0 (<https://www.Rproject.org>) was used for the present study ([@b16-etm-0-0-9115]). Normally distributed continuous variables, including the values of pharmacokinetic parameters and radiomic features, are presented as the mean ± standard deviation. Student\'s t-test was used to compare these variables between the HCC and HMRC groups. The sensitivity, specificity, cut-off value, area under the curve (AUC) and 95% confidence interval (CI) were calculated by receiver operating characteristic (ROC) curve using the 'pROC' package ([@b17-etm-0-0-9115]). Binary logistic regression was used to analyze the variables to differentiate between HCC and HMRC using pharmacokinetic parameters and radiomic features with statistical differences as independent variables, and pathological results as dependent variables. A combination of variables was produced after eliminating the variables. Fisher discriminant analysis (FDA) and leave-one-out cross-validation were used to build linear discriminant models. Two-tailed P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients

The age range of the 35 male and 6 female patients in the HCC group was 25-75 years. The age range of 29 male and 5 female patients in the HMRC group was 26-78 years. No significant differences were observed in the age and sex between the two groups ([Table II](#tII-etm-0-0-9115){ref-type="table"}; P\>0.05).

### Pharmacokinetic parameters and radiomic features

Statistically significant differences in K^trans^, IAUC and HPI values were observed between the HCC and HRMC groups ([Table III](#tIII-etm-0-0-9115){ref-type="table"}). In addition, statistically significant differences were identified in 17 features between the two groups ([Table IV](#tIV-etm-0-0-9115){ref-type="table"}).

### Efficacy of pharmacokinetic parameters and radiomic features

The areas under the ROC curves of pharmacokinetic parameters K^trans^, IAUC and HPI were 0.73 (0.61-0.84, 95% CI),0.77 (0.67-0.88, 95% CI) and 0.67 (0.55-0.79, 95% CI), respectively ([Table III](#tIII-etm-0-0-9115){ref-type="table"} and [Fig. 3](#f3-etm-0-0-9115){ref-type="fig"}). The areas under the ROC curves of the 17 radiomic features with statistical differences were between 0.63 and 0.79 ([Table IV](#tIV-etm-0-0-9115){ref-type="table"} and [Fig. 4](#f4-etm-0-0-9115){ref-type="fig"}). The combination of pharmacokinetic parameters and radiomic features was termed the P-R parameter. The area under the ROC curve of the P-R parameter was 0.86 (95% CI, 0.77-0.94), with a sensitivity of 90.24% and specificity of 73.53% ([Fig. 5](#f5-etm-0-0-9115){ref-type="fig"}).

### Discriminant models based on the radiomic features

The training dataset comprised the 67 radiomic features from the two groups (a total of 75 cases). Accordingly, 14 radiomic features were enrolled to build the discriminant functions required to differentiate HCC from HMRC by calculating the correlation coefficient of intraclass and interclass cases as follows:
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Where Y~i~ (Y~1~, HCC; Y~2~, HMRC) refers to the corresponding scores that determine the tumor classification. If the score of one specified lesion was close to 1, the corresponding case was recognized as HCC. If the score of one specified lesion was close to 2, the case was recognized as HMRC. The FDA model automatically iterated 67 times to achieve accuracy, and the leave-one-out cross-validation method was performed to validate that accuracy ([Table V](#tV-etm-0-0-9115){ref-type="table"}).

Discussion
==========

In the present retrospective study, in order to evaluate HCC and HMRC in the DCE-MRI of lesions, two types of parameters were examined, namely pharmacokinetic parameters and radiomic features, and their values were comprehensively analyzed. Both types of parameters contributed to differentiating HCC from HRMC, and their incorporation improved the efficacy of diagnosis compared with that of either type alone. In addition, the discriminant model based on the radiomic features further enhanced the identification of HCC and HMRC.

In the present study, a number of measures were taken to acquire accurate data ([@b18-etm-0-0-9115]). First, the same MR scanner was used for all patients. Scanning was performed at the end-expiratory breath holding, and 3D non-rigid registration was used to reduce motion artifacts. Contrast agent was simultaneously injected and scanned, and the scanning interval was ≤6 sec in the four following phases to ensure that the images with the most notable enhancement phase of the hepatic artery were captured. A total of 22 phases were scanned to uniformly obtain successive and complete DCE-MRIs. Following an elbow vein injection in all cases, the constants of the injection rate and concentration were determined to ensure the consistency of the contrast agent concentration perfusion to the liver in correspondence with VIF. These measures also prevented any differences caused by various contrast agent concentrations. Secondly, an extended Tofts with dual-input two-compartment model was selected instead of the traditional two-compartment Tofts model. The selected model considered hepatic artery and portal vein input to the liver. Images of the derived radiomic features were selected from the phase when AIF reached the peak; images from this phase were the most representative of disease characteristics and revealed the most information about these characteristics. Thirdly, in image segmentation, vascular, cystic and necrotic areas were avoided by manually drawing the ROIs to ensure the precision of the selected area. Three successive layers were measured to avoid statistical accidental error in the selected lesions. All measures taken in this experiment were conducive to obtaining the accurate values of pharmacokinetic parameters and radiomic features.

As a non-invasive and radiation-free examination method, MRI reveals the internal information of malignant tumors from multiple perspectives using different imaging technology modes. In addition, DCE-MRIs were also indicated in addition to the enhancement characteristics. The perfusion and permeability parameters obtained though the pharmacokinetic model may be used to assess the changes microvascular blood supply to the tumor ([@b22-etm-0-0-9115]). These functional pharmacokinetic parameters, such as K^trans^, IAUC and HPI, may reflect the hemodynamic changes of microvessels in the tumor region, describe the characteristics of tumor lesions and reflect the properties of the lesions from different perspectives to identify tumors to a certain extent ([@b21-etm-0-0-9115],[@b23-etm-0-0-9115]). K^trans^ refers to the rate by which the contrast agent leaks into the extracellular fluid space outside blood vessels and is associated with total blood perfusion, vascular surface area and vascular permeability, thus reflecting the changes in the integrity of tissue microvessels ([@b8-etm-0-0-9115]). Compared with normal tissues, tumor tissues are characterized by an abundance of nascent capillaries, higher microvascular density, larger vascular osmotic surface area, immature microvessels, wider endothelial cell space, incomplete basement membrane and pathological basement membrane structure; this results in increases in tumor tissue microvascular permeability and its K^trans^ value ([@b24-etm-0-0-9115]). In the present study, the K^trans^ value of HCC was higher compared with that of HRMC, indicating that HCC exhibited a higher level of infiltration and permeability compared with those of HRMC on the vascular surface, which may be used for the differential diagnosis of the two lesions. The IAUC value, which was represented by the AUC of the time-concentration curve of the contrast agent, refers to the estimated value of the concentration of the contrast agent in the lesion ([@b9-etm-0-0-9115]). The degree of enhancement varies for lesions with different etiologies, and the IAUC value may be used to identify lesions with different properties ([@b19-etm-0-0-9115],[@b21-etm-0-0-9115]). The results of the present study demonstrated that the IAUC values of the two groups were significantly different, suggesting that IAUC discriminated between the two lesions, which was consistent with a previously published study ([@b25-etm-0-0-9115]). The perfusion parameter HPI is the perfusion ratio of the hepatic artery, and the hepatic artery provides 20-30% of the blood supply under the physiological status of the liver ([@b26-etm-0-0-9115]). The biological behavior of the tumor, which includes tumorigenesis, growth and progression, depends on angiogenesis; therefore, different types of tumors have different blood supplies ([@b26-etm-0-0-9115]). HCC is usually associated with a rich blood supply that mainly originates from the hepatic artery ([@b26-etm-0-0-9115]). However, the richness or poorness of the blood supply of the tumor remains controversial. Previous studies have demonstrated that the hepatic artery is the main source of blood supply for HMRC, regardless of whether the blood supply is rich or poor ([@b19-etm-0-0-9115],[@b27-etm-0-0-9115]). The results of the present study revealed that the HPI values of the two groups were significantly higher compared with those of normal liver tissue, confirming that the hepatic artery was the main source of blood supply for HCC and HMRC tumors. In addition, the HPI values between the two groups were significantly different. This result was consistent with the findings of previous studies, which demonstrated that HPI distinguished HCC from HMRC ([@b19-etm-0-0-9115],[@b27-etm-0-0-9115]). The pharmacokinetic parameters K^trans^, IAUC and HPI reflect the relevant characteristics and properties of lesions from different perspectives, which may be used to identify HCC and HMRC.

Radiomics analysis, which uses the law of change and distribution of image pixel gray value, is used as a mathematical engineering method to express radiomics characteristic information ([@b28-etm-0-0-9115]). The differences in medical images caused by tumor heterogeneity can be quantified using radiomic features. Therefore, radiomics data are potentially associated with pathology ([@b29-etm-0-0-9115]). In addition, radiomics data provide quantitative information about tumor characteristics and have the potential to discover disease characteristics that cannot be observed by the naked eye by combining mathematics, engineering and medical science ([@b30-etm-0-0-9115]). DCE-MRI based on anatomical structure provides functional information, including that on perfusion and metabolism, due to differences in lesion tissues ([@b31-etm-0-0-9115]). The functional information differences in DCE images of biological characteristics and heterogeneity of tumors may be reflected by the values of the radiomic features ([@b31-etm-0-0-9115],[@b32-etm-0-0-9115]). In addition, the present study confirmed that radiomics analysis could be used in the differential diagnosis of HCC and HMRC. In the present study, 67 radiomic features were obtained using OmniKinetic software; however, only 17 features exhibited significant differences, indicating that there were several common features in the tumor characteristics between HCC and HMRC lesions, including blood supply and microvascular changes. Identifying these images by the naked eye is challenging; however, after considerable information screening, highly efficient radiomic features of the identity of the two lesions were obtained. Therefore, radiomic feature analysis may help clinicians identify HCC and HMRC.

In the present study, ROC curves and logistic regression were used for analysis. ROC curves used AUC to evaluate the diagnostic efficiency of each pharmacokinetic parameter and radiomic feature. These high values of AUCs of K^trans^, IAUC, HPI and radiomic features indicate that pharmacokinetic parameters and radiomic features effectively differentiated HCC from HMRC ([Tables III](#tIII-etm-0-0-9115){ref-type="table"} and [IV](#tIV-etm-0-0-9115){ref-type="table"}; [Figs. 3](#f3-etm-0-0-9115){ref-type="fig"} and [4](#f4-etm-0-0-9115){ref-type="fig"}). The AUC of incorporated parameter P-R was 0.86, which was higher compared with that of each of the pharmacokinetic parameters and radiomic features alone. P-R was also demonstrated to have high sensitivity and specificity. Therefore, it can be concluded that combining pharmacokinetics and high-accuracy radiomics improved the detection rate of HCC.

Radiomic features and regression model analysis for evaluating disease diagnosis, development, treatment and prognosis have become popular in recent years ([@b33-etm-0-0-9115]). In the present study, the mathematical model FDA was applied for the analysis of the radiomic features. FDA established the discriminant model to determine the minimum covariance between samples within the same category, and maximum covariance between samples within different categories. The FDA method provided two discriminant functions Y~1~ and Y~2~ for HCC and HMRC, respectively. The category of unidentified liver tumors may be easily recognized through this model, which can automatically draw conclusions using statistical calculations. The FDA model exhibited 89.3% discriminant accuracy and good calibration with 80% accuracy within the datasets of the two groups, thereby showing marked discrimination. To the best of our knowledge, previous studies propounded several radiomics methods for the differentiation of tumors, but a limited number of studies have provided discriminant functions ([@b34-etm-0-0-9115]). Compared with complicated discriminant methods, FDA is an accessible approach that considers intergroup and intragroup covariance ([@b33-etm-0-0-9115]). However, the present study is a pilot study of differentiation research on HCC and HMRC; considering the limited number of cases, no additional patients were used as an external dataset to validate the regression. This will be addressed in a future study.

The present study had several limitations. The MRI system, sequences, time resolution, perfusion time, contrast agent, dose, concentration and injection rate affected the value of the parameters; therefore, the findings might differ from those of previous studies ([@b35-etm-0-0-9115]). However, the study design was based on the same reference standard for all patients. Secondly, the radiomic features extracted from DCE-MRI may be different from those presented in previous studies due to variations in radiomics analysis software ([@b36-etm-0-0-9115]). Thirdly, radiomics and FDA require further multicenter analysis with a large sample size.

In conclusion, the present study demonstrated that DCE-MRI was useful for the differential diagnosis of HCC and HMRC by extracting pharmacokinetic parameters and radiomic features, and the incorporation of the two methods improved the diagnostic efficacy. When mathematical engineering techniques are adequately exploited, the discriminant models based on the radiomic features have potential to diagnose unidentified liver tumors. Thus, this method is worthy of further exploration in clinical settings.
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![Acquisition process of the dual VIF. (A) The ROI of the hepatic artery was placed on the abdominal aorta near the entrance of the celiac trunk, as indicated by the green circle. The ROI of the portal the vein was placed on the main portal vein, as indicated by the blue circle. The area of each centered ROI was approximately two-thirds of its vascular cross-section. (B) AIF is indicated by the green curve, and PIF is indicated by the blue curve. (C) The contrast agent time-concentration curve of the dual VIF was fitted by AIF and PIF. VIF, vascular input function; ROI, region of interest; AIF, arterial input function; PIF, portal input function.](etm-20-04-3643-g00){#f1-etm-0-0-9115}

![Acquisition of pharmacokinetic parameters and radiomic features derived from DCE-MRI. (A) Loading images in dicom format. (B) Manually drawn ROI of the lesion; image segmentation was obtained. (C) Calculation of pharmacokinetic parameters and radiomic features. DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; ROI, region of interest; K^trans^, endothelial transfer constant; IAUC, initial area under the gadolinium concentration curve during the first 60 sec; HPI, hepatic perfusion index; GLCM, gray level co-occurrence matrix; RLM, run length matrix.](etm-20-04-3643-g01){#f2-etm-0-0-9115}

![Receiver operating characteristic curves of the pharmacokinetic parameters. K^trans^, endothelial transfer constant; IAUC, initial area under the gadolinium concentration curve during the first 60 sec; HPI, hepatic perfusion index.](etm-20-04-3643-g02){#f3-etm-0-0-9115}

![Receiver operating characteristic curves of the radiomic features. (A) Max intensity,Median intensity,Mean value,Standard deviation,RMS; (B) MPP, Quantile5,Quantile10,Quantile50,Quantile90,Quantile95; (C) Haralick entropy,Sum entropy, RLM-Max intensity; (D) Mean deviation,Inertia, AngSecMoment. RMS,root mean square; MPP,mean positive pixel; RLM,run length matrix; AngSecMom,angular second moment.](etm-20-04-3643-g04){#f4-etm-0-0-9115}

![Receiver operating characteristic curve of the P-R parameter. P-R, pharmacokinetic parameters and radiomic features.](etm-20-04-3643-g05){#f5-etm-0-0-9115}

###### 

Radiomic features derived from dynamic contrast-enhanced magnetic resonance imaging by OmniKinetics software.

  Type          Radiomic features                                                                                                                                                                                                                                                                                                                                     N
  ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  First order   MinIntensity, MaxIntensity, MedianIntensity, MeanValue, stdDeviation, Variance, VolumeCount, VoxelValueSum, Root Meant Square, Range, MeanDeviation, RelativeDeviation, MinLocation, MaxLocation                                                                                                                                                      14
  Histogram     Energy, Entropy, Kurtosis, Skewness, Uniformity, FrequencySize, Uniformity Positive Pixel, Mean Positive Pixel, Quantile5, Quantile10, Quantile25, Quantile50, Quantile75, Quantile90, Quantile95                                                                                                                                                     15
  GLCM          GlcmEnergy, GlcmEntropy, GlcmBinSize, GlcmTotalFrequency, GlcmMatrixMean, GlcmRelativeFrequency, Inertia, Correlation, InverseDifferenceMoment, ClusterShade, ClusterProminence, HaralickCorrelation, InvalidFeatureName                                                                                                                              13
  Haralick      AngularSecondMoment, Contrast, HaraVariance, sumAverage, sumVariance, sumEntropy, differenceVariance, differenceEntropy, inverseDifferenceMoment                                                                                                                                                                                                      9
  RLM           MaxIntensity, MinIntensity, MinSize, NumberOfIntensityBins, MaxSize, NumberOfSizeBins, ShortRunEmphasis, LongRunEmphasis, GreyLevelNonuniformity, RunLengthNonuniformity, LowGreyLevelRunEmphasis, HighGreyLevelRunEmphasis, ShortRunLowGreyLevelEmphasis, ShortRunHighGreyLevelEmphasis, LongRunLowGreyLevelEmphasis, LongRunHighGreyLevelEmphasis   16

GLCM, gray level co-occurrence matrix; RLM, run length matrix.

###### 

Clinicopathological characteristics of patients with HCC and HMRC.

  Characteristic   HCC (n=41)    HMRC (n=34)   t/χ^2^   P-value
  ---------------- ------------- ------------- -------- ---------
  Age, years       51.59±10.25   53.88±13.21   0.61     0.54
  Sex, n (%)                                             
       Male        35 (85.37)    29 (85.29)    \<0.01   \>0.99
       Female      6 (14.63)     5 (14.71)               

HCC, hepatocellular carcinoma; HMRC, hepatic metastasis of rectal cancer.

###### 

Pharmacokinetic parameters of HCC and HMRC.

  Parameter           HCC (n=41)   HMRC (n=34)   AUC (95 %CI)       Cut-off   Sensitivity   Specificity   Youden\'s index   P-value
  ------------------- ------------ ------------- ------------------ --------- ------------- ------------- ----------------- ---------
  K^trans^, min^-1^   1.11±0.73    0.63±0.47     0.73 (0.61-0.84)   0.45      0.88          0.53          0.41              0.000
  IAUC, mmol x min    1.43±0.56    0.93±0.41     0.77 (0.67-0.88)   1.18      0.68          0.79          0.48              0.000
  HPI                 0.73±0.14    0.61±0.18     0.67 (0.55-0.79)   0.59      0.83          0.50          0.33              0.004

HCC, hepatocellular carcinoma; HMRC, hepatic metastasis of rectal cancer; K^trans^, endothelial transfer constant; IAUC, initial area under the gadolinium concentration curve during the first 60 sec; HPI, hepatic perfusion index.

###### 

Radiomic features of HCC and HMR.

  Type          Feature              HCC (n=41)       HMRC (n=34)      P-value   AUC (95%CI)        Cut-off   Sensitivity   Specificity   Youden\'s index
  ------------- -------------------- ---------------- ---------------- --------- ------------------ --------- ------------- ------------- -----------------
  First order   MaxIntensity         801.47±317.41    1143.22±307.91   \<0.01    0.78 (0.67-0.88)   873.50    0.85          0.62          0.47
                Median Intensity     518.8±176.15     700.36±198.87    \<0.01    0.76 (0.65-0.87)   651.89    0.61          0.82          0.43
                MeanValue            516.45±173.44    698.78±192.66    \<0.01    0.77 (0.66-0.88)   635.66    0.61          0.82          0.43
                Standard Deviation   94.17±47.83      137.62±52.93     \<0.01    0.75 (0.64-0.86)   92.23     0.83          0.59          0.42
                RMS                  526.63±174.84    714.08±192.79    \<0.01    0.77 (0.66-0.88)   648.53    0.61          0.82          0.43
                MeanDeviation        -261.45±173.44   -443.77±192.66   \<0.01    0.77 (0.66-0.88)   -380.7    0.61          0.82          0.43
  Histogram     MPP                  516.45±173.44    698.78±192.66    \<0.01    0.77 (0.66-0.88)   635.66    0.61          0.82          0.43
                Quantile10           392.18±153.75    519.74±173.69    \<0.01    0.71 (0.60-0.83)   406.41    0.80          0.59          0.39
                Quantile50           518.3±176.15     700.15±198.77    \<0.01    0.76 (0.65-0.87)   651.09    0.61          0.82          0.43
                Quantile75           582.57±189.87    790.95±210.68    \<0.01    0.77 (0.67-0.88)   652.89    0.78          0.65          0.43
                Quantile90           635.34±206.64    875.33±222.91    \<0.01    0.79 (0.69-0.89)   796.89    0.66          0.82          0.48
                Quantile95           667.39±219.68    923.93±232.64    \<0.01    0.79 (0.68-0.89)   796.24    0.76          0.74          0.49
  GLCM          Inertia              572.99±381.47    400.14±223.26    0.02      0.63 (0.50-0.76)   489.09    0.73          0.53          0.26
  Haralick      Entropy              0.64±0.06        0.68±0.05        \<0.01    0.71 (0.59-0.83)   0.62      0.90          0.47          0.37
                AngSecMoment         0.0014±0.0011    0.0009±0.0004    0.01      0.69 (0.56-0.81)   0.001     0.73          0.59          0.32
                SumEntropy           0.82±0.05        0.80±0.06        0.04      0.63 (0.49-0.76)   0.77      0.88          0.41          0.29
  RLM           MaxIntensity         801.47±317.41    1143.22±307.91   \<0.01    0.78 (0.67-0.88)   873.50    0.85          0.62          0.47

HCC, hepatocellular carcinoma; HMRC, hepatic metastasis of rectal cancer; AUC, area under the curve; RMS, root mean square; MPP, mean positive pixel; GLCM, gray level co-occurrence matrix; RLM, run length matrix.

###### 

Results of the discriminant models based on the radiomic features.

                                   Prediction                                
  -------------------------------- ------------ ---- ----------- ----------- ------
  FDA training dataset             HCC          41   39 (95.1)   2 (4.9)     89.3
                                   HMRC         34   6 (17.6)    28 (82.4)    
  Leave-one-out cross-validation   HCC          41   35 (85.4)   6 (14.6)    80.0
                                   HMRC         34   9 (26.5)    25 (73.5)    

HCC, hepatocellular carcinoma; HMRC, hepatic metastasis of rectal cancer; FDA, Fisher\'s discriminant analysis.

[^1]: *Abbreviations:* HCC, hepatocellular carcinoma; HMRC, hepatic metastasis of rectal cancer; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; FDA, Fisher\'s discriminant analysis; IAUC, initial area under the gadolinium concentration curve during the first 60 sec; HPI, hepatic perfusion index
